Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSV | O60911 | 4/20 | 0.62 |
| ▸ | CTSL | P07711 | 4/20 | 0.62 |
| ▸ | NPC1 | O15118 | 2/20 | 0.62 |
| ▸ | MTOR | P42345 | 1/20 | 0.62 |
| ▸ | HPGD | P15428 | 6/20 | 0.60 |
| ▸ | LMNA | P02545 | 4/20 | 0.60 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.60 |
| ▸ | TUBB4A | P04350 | 1/20 | 0.60 |
| ▸ | TP53 | P04637 | 1/20 | 0.60 |
| ▸ | TUBB | P07437 | 1/20 | 0.60 |
| ▸ | TUBA3C | P0DPH7 | 1/20 | 0.60 |
| ▸ | TUBA1B | P68363 | 1/20 | 0.60 |
| ▸ | TUBA4A | P68366 | 1/20 | 0.60 |
| ▸ | TUBB4B | P68371 | 1/20 | 0.60 |
| ▸ | TUBB3 | Q13509 | 1/20 | 0.60 |
| ▸ | TUBB2A | Q13885 | 1/20 | 0.60 |
| ▸ | TUBB8 | Q3ZCM7 | 1/20 | 0.60 |
| ▸ | TUBA3E | Q6PEY2 | 1/20 | 0.60 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.60 |
| ▸ | TUBA1A | Q71U36 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29411907 | 1.00 | CTSV (0.62) | CTSVCTSLNPC1MTORHPGD | |
| SCHEMBL26846989 | 0.89 | HPGD (0.58) | CTSVCTSLNPC1MTORHPGD | |
| SCHEMBL26722962 | 0.86 | HPGD (0.56) | CTSVCTSLNPC1MTORHPGD | |
| SCHEMBL6294903 | 0.86 | ALDH1A1 (0.68) | CTSVCTSLNPC1MTORHPGD | |
| SCHEMBL1819378 | 0.86 | KMT2A (0.66) | CTSVCTSLNPC1MTORHPGD | |
| SCHEMBL311746 | 0.83 | CTSV (0.55) | CTSVCTSLNPC1MTORHPGD | |
| SCHEMBL2799492 | 0.83 | HPGD (0.73) | CTSVCTSLNPC1MTORHPGD | |
| SCHEMBL26847051 | 0.83 | HPGD (0.57) | CTSVCTSLNPC1HPGDLMNA | |
| SCHEMBL26846933 | 0.81 | KDM4E (0.52) | CTSVCTSLNPC1MTORHPGD | |
| SCHEMBL26847068 | 0.80 | HPGD (0.64) | CTSVCTSLNPC1HPGDLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240002348-A1 | QUINOLONE COMPOUNDS AND PROCESS FOR PREPARATION THEREOF | COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH AN INDIAN REGISTERED BODY INCORPORATED UNDER THE REGN. OF SOC. ACT (ACT XXI OF 1860) (IN) | 2024-01-04 | — | — | US | disclosed |
| EP-4204410-A1 | QUINOLONE COMPOUNDS AND PROCESS FOR PREPARATION THEREOF | Council of Scientific & Industrial Research, an Indian registered body incorporated under the Registration of Societies Act (Act XXI of 1860) (IN) | 2023-07-05 | — | — | EP | disclosed |
| EP-3112348-A1 | SYNTHESIS AND ANTICANCER ACTIVITY OF ARYL AND HETEROARYL-QUINOLIN DERIVATIVES | Tairx, Inc. (TW) | 2017-01-04 | — | — | EP | disclosed |
| EP-2593435-B1 | SYNTHESIS AND ANTICANCER ACTIVITY OF ARYL AND HETEROARYL-QUINOLIN DERIVATIVES | TAIRX INC (TW) | 2016-09-07 | — | — | EP | disclosed |
| US-8524740-B2 | Synthesis and anticancer activity of aryl and heteroaryl-quinolin derivatives | TAIRX, INC. (TW) | 2013-09-03 | — | — | US | disclosed |
| EP-2593435-A1 | SYNTHESIS AND ANTICANCER ACTIVITY OF ARYL AND HETEROARYL-QUINOLIN DERIVATIVES | Tairx, Inc. (TW) | 2013-05-22 | — | — | EP | disclosed |
| US-20120015908-A1 | SYNTHESIS AND ANTICANCER ACTIVITY OF ARYL AND HETEROARYL-QUINOLIN DERIVATIVES | Efficient Pharma Management Corporate (TW) | 2012-01-19 | — | — | US | disclosed |
| WO-2012009519-A1 | SYNTHESIS AND ANTICANCER ACTIVITY OF ARYL AND HETEROARYL-QUINOLIN DERIVATIVES | EFFICIENT PHARMA MANAGEMENT CORP. (TW) | 2012-01-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120015908-A1 | SYNTHESIS AND ANTICANCER ACTIVITY OF ARYL AND HETEROARYL-QUINOLIN DERIVATIVES | SLC22A8, ABCC8, CYP2C8 | CTSV 1122/4885CTSL 1365/4885NPC1 874/4885 |
| US-20240002348-A1 | QUINOLONE COMPOUNDS AND PROCESS FOR PREPARATION THEREOF | SQLE, NQO2, CYP1B1 | CTSV 1927/4885CTSL 3665/4885NPC1 4642/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.